Carbon Ion Radiation With Image-Guided Boost for Localized Prostate Cancer
Tests carbon ion radiation with an image-guided boost in men with localized prostate cancer.
Plain-language title generated from the registry record
Registry title: Functional Image-Guided Carbon Ion Irradiation With Simultaneous Integrated Boost for Prostate Cancer
Key facts
- Where
- Shanghai, ChinaSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 45 and 85 years old?
Source: NCT05010343, who can take part
Where in China
- Shanghai Proton and Heavy Ion CenterShanghai, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Shanghai Proton and Heavy Ion Center
- Trial code
- NCT05010343
- Record updated
- 15 November 2021
- Original description
This is a phase II randomized controlled clinical trial to assess the toxicities and clinical efficacy of prostate specific membrane antigen (PSMA) positron emission tomography / computed tomography (PET/CT) and multi- parameter Magnetic Resonance Imaging (MRI) guided simultaneous integrated boost for prostate cancer.Read full original descriptionShow less
Functional Image-Guided Carbon Ion Irradiation With Simultaneous Integrated Boost for Prostate Cancer: a Phase II Randomized Controlled Clinical Trial
This is a phase II randomized controlled clinical trial to assess the toxicities and clinical efficacy of prostate specific membrane antigen (PSMA) positron emission tomography / computed tomography (PET/CT) and multi- parameter Magnetic Resonance Imaging (MRI) guided simultaneous integrated boost for prostate cancer.
Inclusion: Pathologically confirmed adenocarcinoma of prostate; Stage cT1-3N0M0 localized prostate cancer; performed PSMA PET/CT and mpMRI before treatment; No lymph nodes or distant metastasis; Age ≥ 45 and < 85 years of age; Karnofsky Performance Score ≥70; No previous pelvic radiation therapy (RT); No previous prostatectomy; No previous invasive cancer (within 5 years before the prostate cancer diagnosis); Ability to understand character and individual consequences of the clinical trial; Willing to sign the written informed consent; Informed consent must be signed before the enrollment in the trial.
Exclusion: Previous pelvic radiotherapy; Previous prostatectomy; No pathologically confirmed adenocarcinoma of the prostate; Pelvic lymph node metastasis (N1); Distant metastasis (M1).